US9650373B2 - Synthesis of 2-carboxamide cycloamino urea derivatives - Google Patents
Synthesis of 2-carboxamide cycloamino urea derivatives Download PDFInfo
- Publication number
- US9650373B2 US9650373B2 US13/985,069 US201213985069A US9650373B2 US 9650373 B2 US9650373 B2 US 9650373B2 US 201213985069 A US201213985069 A US 201213985069A US 9650373 B2 US9650373 B2 US 9650373B2
- Authority
- US
- United States
- Prior art keywords
- formula
- compound
- solvent
- contacting
- tetrahydrofuran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 [1*]C1=NC=CC(C2=C([2*])N=C(NC(=O)N3CCC[C@H]3C(N)=O)S2)=C1 Chemical compound [1*]C1=NC=CC(C2=C([2*])N=C(NC(=O)N3CCC[C@H]3C(N)=O)S2)=C1 0.000 description 14
- OMMLUKLXGSRPHK-UHFFFAOYSA-N CC(C)(C)C(C)(C)C Chemical compound CC(C)(C)C(C)(C)C OMMLUKLXGSRPHK-UHFFFAOYSA-N 0.000 description 3
- XRLDSWLMHUQECH-UHFFFAOYSA-N NC(=O)C1CCCC1 Chemical compound NC(=O)C1CCCC1 XRLDSWLMHUQECH-UHFFFAOYSA-N 0.000 description 2
- LKVUPRMMDDGDEB-UHFFFAOYSA-N Br.C.C.C.CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(N)=N1.CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(NC(=O)OC2=CC=CC=C2)=N1.O=C(Cl)OC1=CC=CC=C1 Chemical compound Br.C.C.C.CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(N)=N1.CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(NC(=O)OC2=CC=CC=C2)=N1.O=C(Cl)OC1=CC=CC=C1 LKVUPRMMDDGDEB-UHFFFAOYSA-N 0.000 description 1
- SUNRMZITDGXEGS-UHFFFAOYSA-N Br.C.C.CC(=O)CC1=CC(C(C)(C)C(F)(F)F)=NC=C1.CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(N)=N1.NC(N)=S.O=C1CCC(=O)N1Br Chemical compound Br.C.C.CC(=O)CC1=CC(C(C)(C)C(F)(F)F)=NC=C1.CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(N)=N1.NC(N)=S.O=C1CCC(=O)N1Br SUNRMZITDGXEGS-UHFFFAOYSA-N 0.000 description 1
- NKLQGMLMQZFFSJ-BWDDHGNTSA-N Br.C.C.CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(N)=N1.CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(N)=N1.CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1.CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(NC(=O)OC2=CC=CC=C2)=N1.NC(=O)[C@@H]1CCCN1.O=C(Cl)OC1=CC=CC=C1 Chemical compound Br.C.C.CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(N)=N1.CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(N)=N1.CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1.CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(NC(=O)OC2=CC=CC=C2)=N1.NC(=O)[C@@H]1CCCN1.O=C(Cl)OC1=CC=CC=C1 NKLQGMLMQZFFSJ-BWDDHGNTSA-N 0.000 description 1
- GIMHTUSRCNPLSI-UHFFFAOYSA-N Br.CC1=C(C2=CC(C(C)(C)C)=NC=C2)SC(N)=N1 Chemical compound Br.CC1=C(C2=CC(C(C)(C)C)=NC=C2)SC(N)=N1 GIMHTUSRCNPLSI-UHFFFAOYSA-N 0.000 description 1
- GANQIAKKZFELHD-UHFFFAOYSA-N C.C.C.CC(=O)CC1=CC(C(C)(C)C(F)(F)F)=NC=C1.CC(C)NC(C)C.CC1=CC(C(C)(C)C(F)(F)F)=NC=C1.CN1O(C)[Li]OC1(C)CC1=CC(C(C)(C)C(F)(F)F)=NC=C1.CON(C)C(C)=O Chemical compound C.C.C.CC(=O)CC1=CC(C(C)(C)C(F)(F)F)=NC=C1.CC(C)NC(C)C.CC1=CC(C(C)(C)C(F)(F)F)=NC=C1.CN1O(C)[Li]OC1(C)CC1=CC(C(C)(C)C(F)(F)F)=NC=C1.CON(C)C(C)=O GANQIAKKZFELHD-UHFFFAOYSA-N 0.000 description 1
- RJLNAAFLTAZTNP-UHFFFAOYSA-N C.C.C.CC(=O)CC1=CC(C(C)(C)C)=NC=C1.CC(=O)N(C)C.CC1=CC(C(C)(C)C(F)(F)F)=NC=C1 Chemical compound C.C.C.CC(=O)CC1=CC(C(C)(C)C)=NC=C1.CC(=O)N(C)C.CC1=CC(C(C)(C)C(F)(F)F)=NC=C1 RJLNAAFLTAZTNP-UHFFFAOYSA-N 0.000 description 1
- XUHPCDHETNCMEI-UHFFFAOYSA-N C.C.CC(=O)CC1=CC(C(C)(C)C(F)(F)F)=NC=C1.CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(N)=N1.NC(N)=S.[BrH2+] Chemical compound C.C.CC(=O)CC1=CC(C(C)(C)C(F)(F)F)=NC=C1.CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(N)=N1.NC(N)=S.[BrH2+] XUHPCDHETNCMEI-UHFFFAOYSA-N 0.000 description 1
- FMHMAZBFBSTJKS-FAYOTWMKSA-N C.C.CC(=O)[C@@H]1CCCN1C(=O)NC1=NC(C)=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)S1.CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(NC(=O)OC2=CC=CC=C2)=N1.CI.NC(=O)C1CCCC1 Chemical compound C.C.CC(=O)[C@@H]1CCCN1C(=O)NC1=NC(C)=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)S1.CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(NC(=O)OC2=CC=CC=C2)=N1.CI.NC(=O)C1CCCC1 FMHMAZBFBSTJKS-FAYOTWMKSA-N 0.000 description 1
- ISYBPYQAHLOJAS-UHFFFAOYSA-N CC(=O)CC1=CC(C(C)(C)C)=NC=C1.CC1=CC(C(C)(C)C(F)(F)F)=NC=C1.CON(C)C(C)=O Chemical compound CC(=O)CC1=CC(C(C)(C)C)=NC=C1.CC1=CC(C(C)(C)C(F)(F)F)=NC=C1.CON(C)C(C)=O ISYBPYQAHLOJAS-UHFFFAOYSA-N 0.000 description 1
- IHGVAVLSTPCCJP-UHFFFAOYSA-N CC(C)(C(F)(F)F)c1nccc(-c2c(C)nc(N)[s]2)c1 Chemical compound CC(C)(C(F)(F)F)c1nccc(-c2c(C)nc(N)[s]2)c1 IHGVAVLSTPCCJP-UHFFFAOYSA-N 0.000 description 1
- QSXSOPISJRLHSZ-UHFFFAOYSA-N CC(C)(C(F)(F)F)c1nccc(CC(C)=O)c1 Chemical compound CC(C)(C(F)(F)F)c1nccc(CC(C)=O)c1 QSXSOPISJRLHSZ-UHFFFAOYSA-N 0.000 description 1
- STUWGJZDJHPWGZ-LBPRGKRZSA-N CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1 Chemical compound CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1 STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 1
- CTQMACUVNNRARX-UHFFFAOYSA-N CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(NC(=O)OC2=CC=CC=C2)=N1.O=C(Cl)OC1=CC=CC=C1 Chemical compound CC1=C(C2=CC(C(C)(C)C(F)(F)F)=NC=C2)SC(NC(=O)OC2=CC=CC=C2)=N1.O=C(Cl)OC1=CC=CC=C1 CTQMACUVNNRARX-UHFFFAOYSA-N 0.000 description 1
- OGBZELSUKYODHJ-UHFFFAOYSA-N CC1=CC(C(C)(C)C)=NC=C1 Chemical compound CC1=CC(C(C)(C)C)=NC=C1 OGBZELSUKYODHJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/26—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention is directed to processes for preparing 2-carboxamide cycloamino urea derivatives, and useful intermediates therefore.
- Phosphatidylinositol 3-kinases comprise a family of lipid kinases that catalyze the transfer of phosphate to the D-3′ position of inositol lipids to produce phosphoinositol-3-phosphate (PIP), phosphoinositol-3,4-diphosphate (PIP2) and phosphoinositol-3,4,5-triphosphate (PIP3), which, in turn, act as second messengers in signaling cascades by docking proteins containing pleckstrin-homology, FYVE, Phox and other phospholipid-binding domains into a variety of signaling complexes often at the plasma membrane.
- PIP phosphoinositol-3-phosphate
- PIP2 phosphoinositol-3,4-diphosphate
- PIP3 phosphoinositol-3,4,5-triphosphate
- PCT Publication No. WO 2010/029082 discloses PI3K inhibitors.
- the compounds disclosed therein include (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-( ⁇ 4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl ⁇ -amide) (i.e., the compound of formula (10)).
- the present invention is directed to improved processes for preparing compounds of the formula (X), specifically the compound of formula (10), as well as useful intermediates such as compounds of the formula (I), specifically the compound of formula (1):
- a process for making a compound of formula (X), comprising contacting a compound of formula (I) with a solvent and a base, and contacting the resulting mixture with a compound of formula (II), such that a compound of formula (III) is produced (STEP A); contacting a compound of formula (III) with thiourea, in a reaction mixture comprising a solvent and an oxidizing agent, such that a compound of formula (V) is produced (STEP B); contacting a compound of formula (V) with a compound of formula (VII), in a reaction mixture comprising a solvent and a base, such that a compound of formula (VIII) is produced (STEP C); and contacting a compound of formula (VIII) with the compound of formula (IX) in a reaction mixture comprising a solvent, such that a compound of formula (X) is produced (STEP D).
- the solvent of Step A comprises one or more solvents selected from aromatic solvents, aliphatic solvents, halogenated solvents, polar aprotic solvents and ethereal solvents.
- the solvent of Steps B, C and D independently comprises one or more solvents selected from aromatic solvents, aliphatic solvents, halogenated solvents, ethereal solvents, polar aprotic solvents, water and alcohol solvents.
- a process for making the compound of formula (10), comprising contacting the compound of formula (1) with a solvent and a base, and contacting the resulting mixture with a compound of formula (2), such that the compound of formula (3) is produced (STEP A).
- the compound of formula (3) is then contacted with thiourea, in a reaction mixture comprising a solvent and an oxidizing agent, such that the compound of formula (5) is produced (STEP B).
- the compound of formula (5) is next contacted with the compound of formula (7), in a reaction mixture comprising a solvent and a base, such that the compound of formula (8) is produced (STEP C).
- the compound of formula (8) is contacted with the compound of formula (IX), in a reaction mixture comprising a solvent, such that the compound of formula (10) is produced (STEP D).
- the solvent of Step A comprises tetrahydrofuran
- the base of Step A is lithium diisopropylamide
- the solvent of Step B comprises toluene and ethanol
- the oxidizing agent of Step B is N-bromosuccinimide
- the solvent of Step C comprises tetrahydrofuran
- the base of Step C is pyridine
- the solvent of Step D comprises tetrahydrofuran and water.
- processes and intermediate compounds useful for the preparation of PI3K inhibitors are advantageous over previously-known processes (see, e.g., PCT Publication No. WO 2010/029082) in several ways.
- the instant processes do not employ transition metal-catalyzed reactions, and therefore do not require steps to remove transition metal byproducts, residues and impurities.
- the instant processes do not require reactions to be performed at very low temperatures (e.g., ⁇ 78° C.).
- Step A contacting a compound of formula (I) with a solvent and a base, and contacting the resulting mixture with a compound of formula (II), such that a compound of formula (III) is produced:
- Step B contacting a compound of formula (III) with thiourea, in a reaction mixture comprising a solvent and an oxidizing agent [X+], such that a compound of formula (V) is produced:
- R 1 is a cyclic or acyclic, branched or linear C 1 -C 7 alkyl, which may be optionally substituted one or more times with deuterium, halogen, or C 3 -C 5 cycloalkyl;
- R 2 is selected from (1) hydrogen, (2) fluoro, chloro, (3) optionally substituted methyl, wherein said substituents are independently selected from one or more, preferably one to three of the following moieties: deuterium, fluoro, chloro, dimethylamino; and
- X is selected from the group consisting of halide, carboxylate and sulfonate.
- Step C contacting a compound of formula (V) with a compound of formula (VII), in a reaction mixture comprising a solvent and a base, such that a compound of formula (VIII) is produced:
- Step D contacting a compound of formula (VIII) with the compound of formula (IX), in a reaction mixture comprising a solvent, such that a compound of formula (X) is produced:
- R 1 is a cyclic or acyclic, branched or linear C 1 -C 7 alkyl, which may be optionally substituted one or more times with deuterium, halogen, or C 3 -C 5 cycloalkyl;
- R 2 is selected from (1) hydrogen, (2) fluoro, chloro, (3) optionally substituted methyl, wherein said substituents are independently selected from one or more, preferably one to three of the following moieties: deuterium, fluoro, chloro, dimethylamino; and
- X is selected from the group consisting of halide, carboxylate and sulfonate
- R 3 and R 4 are independently selected from the group consisting of halogen, heteroaryl, alkoxy and aryloxy;
- heteroaryl, alkoxy and aryloxy moieties of R 3 and R 4 are optionally, independently substituted one or more times with alkyl, alkoxy, halogen and nitro.
- a process for making a compound of formula (X) comprising the following steps: Step A: contacting a compound of formula (I) with a solvent and a base, and contacting the resulting mixture with a compound of formula (II), such that a compound of formula (III) is produced; Step B: contacting a compound of formula (III) with thiourea, in a reaction mixture comprising a solvent and an oxidizing agent, such that a compound of formula (V) is produced; Step C: contacting a compound of formula (V) with a compound of formula (VII), in a reaction mixture comprising a solvent and a base, such that a compound of formula (VIII) is produced; and Step D: contacting a compound of formula (VIII) with the compound of formula (IX), in a reaction mixture comprising a solvent, such that a compound of formula (X) is produced; wherein R 1 , R 2 , R 3 , R 4 and X are as defined above.
- the solvent of Step A comprises one or more solvents selected from aromatic solvents, aliphatic solvents, halogenated solvents, polar aprotic solvents and ethereal solvents.
- aromatic solvents include benzene, toluene, xylenes, nitrobenzene, anisole, ethylbenzene, and pyridine.
- aliphatic solvents include petroleum ether, ligroin, n-hexane, cyclohexane and heptane.
- Non-limiting examples of halogenated solvents include chloroform, chlorobenzene and perfluorohexane.
- Non-limiting examples of polar aprotic solvents include dimethylsulfoxide, dimethylformamide and N-methyl pyrrolidone.
- Non-limiting examples of ethereal solvents include diethyl ether, methyl tertiary-butyl ether, tetrahydrofuran, 2-methyl tetrahydrofuran and dimethoxyethane.
- the solvent of Step A is an aprotic, organic solvent.
- the solvent of Step A comprises tetrahydrofuran.
- the solvent of Steps B, C and D independently comprises one or more solvents selected from aromatic solvents, aliphatic solvents, halogenated solvents, ethereal solvents, polar aprotic solvents, water and alcohol solvents.
- alcohol solvents include ethanol, tertiary-butanol and ethylene glycol.
- Other alcohol solvents are known to those skilled in the art.
- the solvent of Step B comprises an aromatic solvent and an alcohol solvent.
- the solvent of Step B comprises toluene and ethanol.
- the solvent of Step C comprises an ethereal solvent.
- the solvent of Step C comprises tetrahydrofuran.
- the solvent of Step D comprises and ethereal solvent and water.
- the solvent of Step D comprises tetrahydrofuran and water.
- the base of Step A is a strong base.
- Strong bases include the conjugate bases of hydrocarbons, ammonia, amines and dihydrogen.
- Non-limiting examples of strong bases include n-butyllithium, n-hexyllithium, sodium hydride and lithium diisopropylamide.
- Other strong bases are known to those skilled in the art.
- the base of Step A is lithium diisopropylamide. Methods of preparing lithium diisopropylamide are known to those of skill in the art (see, e.g., Smith, A. P.; Lamba, J. J. S.; Fraser, C. L., Org. Syn. Col. Vol. 10: 107, (2004)).
- the lithium diisopropylamide is prepared by the deprotonation of isopropylamine with an alkyllithium base such as n-butyllithium, n-hexyllithium or n-octyllithium. Safety and economic considerations may influence the selection of reagents used for the preparation of lithium diisopropylamide (see, e.g., Chapter 3: Reagent Selection, in “Practical Process Research and Development”, Academic Press, 2000).
- the lithium diisopropylamide is prepared by the deprotonation of diisopropylamine with n-hexyllithium.
- solvents such as THF
- the base of Step C is an amine.
- amine bases include tertiary-butylamine, piperidine, triethylamine, 1,8-Diazabicyclo[5.4.0]undec-7-ene and pyridine.
- Other amine bases are known to those skilled in the art.
- the base of Step C is pyridine.
- the oxidizing agent of Step B is an electrophilic halogen reagent.
- electrophilic halogen reagents are known to the skilled practitioner, including dibromine, diiodine, dichlorine, sulfuryl chloride, N-bromosuccinimide, N-iodosuccinimide, N-chlorosuccinimide and 1,3-dibromo-5,5-dimethylhydantoin.
- the oxidizing agent of Step B is N-bromosuccinimide.
- the oxidizing agent of Step B is N-bromosuccinimide, and the subsequent mixture is diluted with an anti-solvent agent.
- the anti-solvent is isopropyl acetate.
- X is selected from the group consisting of halide, carboxylate, and sulfonate.
- X is a halide.
- X is bromine.
- the solvent of Step A comprises tetrahydrofuran
- the base of Step A is lithium diisopropylamide
- the solvent of Step B comprises toluene and ethanol
- the oxidizing agent of Step B is N-bromosuccinimide
- the solvent of Step C comprises tetrahydrofuran
- the base of Step C is pyridine
- the solvent of Step D comprises tetrahydrofuran and water.
- R 1 is a cyclic or acyclic, branched or linear C 1 -C 7 alkyl, all of which may be optionally substituted one or more times with deuterium, halogen, or C 3 -C 5 cycloalkyl. In other embodiments, R 1 is a branched or linear C 1 -C 7 alkyl that is optionally substituted one or more times with halogen. In a preferred embodiment, R 1 is
- R 2 represents (1) hydrogen, (2) fluoro, chloro, (3) optionally substituted methyl, wherein said substituents are independently selected from one or more, preferably one to three of the following moieties: deuterium, fluoro, chloro, dimethylamino.
- R 2 is selected from hydrogen, cyclic or acyclic, branched or linear C 1 -C 7 alkyl, and halogen wherein the alkyl is optionally substituted one or more times with deuterium, fluorine, chlorine and dimethylamino.
- R 2 is a branched or linear C 1 -C 7 alkyl.
- R 2 is methyl.
- R 3 and R 4 are independently selected from the group consisting of halogen, heteroaryl, alkoxy and aryloxy; wherein the heteroaryl, alkoxy and aryloxy moieties of R 3 and R 4 are optionally, independently substituted one or more times with alkyl, alkoxy, halogen and nitro.
- R 3 is aryloxy and R 4 are both heteroaryl.
- R 3 is aryloxy and R 4 is halogen.
- R 3 is phenoxy and R 4 is chlorine.
- R 1 is
- R 2 is methyl, R 3 is phenoxy, R 4 is chlorine and X is bromine.
- the compound of formula (I) is first contacted with the compound of formula (II) in a reaction mixture comprising a base and solvent, and second optionally contacted with a reaction mixture comprising an aqueous acid or base resulting in the pH of the aqueous phase to be within the range 2 ⁇ pH ⁇ 4, preferably pH 3.
- the base is lithium diisopropylamide and the first solvent is THF, wherein the reaction mixture is maintained such that the internal temperature remains less than ⁇ 5° C., preferably at ⁇ 15° C.
- the pH of the aqueous phase is adjusted to pH 3 with a reaction mixture comprising sulfuric acid, water and toluene.
- the compound of formula (VIII) is contacted with the compound of formula (IX) in a reaction mixture comprising a first solvent, such that the compound of formula (X) is formed.
- An aromatic solvent is then added to the mixture, followed by removal of the first solvent by distillation, resulting in the precipitation of the compound of formula (X).
- the aromatic solvent is toluene.
- Step A contacting the compound of formula (1) with a solvent and a base, and contacting the resulting mixture with the compound of formula (2), such that the compound of formula (3) is produced:
- Step B contacting the compound of formula (3) with thiourea, in a reaction mixture comprising a solvent and an oxidizing agent [Br+], such that the compound of formula (5) is produced:
- Step C contacting the compound of formula (5) with the compound of formula (7), in a reaction mixture comprising a solvent and a base, such that the compound of formula (8) is produced:
- Step D contacting the compound of formula (8) with the compound of formula (IX), in a reaction mixture comprising a solvent, such that the compound of formula (10) is produced:
- the solvent of Step A comprises one or more solvents selected from aromatic solvents, aliphatic solvents, halogenated solvents, polar aprotic solvents and ethereal solvents.
- aromatic solvents include benzene, toluene, xylenes, nitrobenzene, anisole, ethylbenzene, and pyridine.
- aliphatic solvents include petroleum ether, ligroin, n-hexane, cyclohexane and heptane.
- Non-limiting examples of halogenated solvents include chloroform, chlorobenzene and perfluorohexane.
- Non-limiting examples of polar aprotic solvents include dimethylsulfoxide, dimethylformamide and N-methyl pyrrolidone.
- Non-limiting examples of ethereal solvents include diethyl ether, methyl tertiary-butyl ether, tetrahydrofuran, 2-methyl tetrahydrofuran and dimethoxyethane.
- the solvent of Step A is an aprotic, organic solvent.
- the solvent of Step A comprises tetrahydrofuran.
- the solvent of Steps B, C and D independently comprises one or more solvents selected from aromatic solvents, aliphatic solvents, halogenated solvents, ethereal solvents, polar aprotic solvents, water and alcohol solvents.
- alcohol solvents include ethanol, tertiary-butanol and ethylene glycol.
- Other alcohol solvents are known to those skilled in the art.
- the solvent of Step B comprises an aromatic solvent and an alcohol solvent.
- the solvent of Step B comprises toluene and ethanol.
- the solvent of Step C comprises an ethereal solvent.
- the solvent of Step C comprises tetrahydrofuran.
- the solvent of Step D comprises and ethereal solvent and water.
- the solvent of Step D comprises tetrahydrofuran and water.
- the base of Step A is a strong base.
- Strong bases include the conjugate bases of hydrocarbons, ammonia, amines and dihydrogen.
- Non-limiting examples of strong bases include n-butyllithium, n-hexyllithium, sodium hydride and lithium diisopropylamide.
- Other strong bases are known to those skilled in the art.
- the base of Step A is lithium diisopropylamide. Methods of preparing lithium diisopropylamide are known to those of skill in the art (see, e.g., Smith, A. P.; Lamba, J. J. S.; Fraser, C. L., Org. Syn. Col. Vol. 10: 107, (2004)).
- the lithium diisopropylamide is prepared by the deprotonation of isopropylamine with an alkyllithium base such as n-butyllithium, n-hexyllithium or n-octyllithium. Safety and economic considerations may influence the selection of reagents used for the preparation of lithium diisopropylamide (see, e.g., Chapter 3: Reagent Selection, in “Practical Process Research and Development”, Academic Press, 2000).
- the lithium diisopropylamide is prepared by the deprotonation of diisopropylamine with n-hexyllithium.
- solvents such as THF
- the base of Step C is an amine.
- amine bases include tertiary-butylamine, piperidine, triethylamine, 1,8-Diazabicyclo[5.4.0]undec-7-ene and pyridine.
- Other amine bases are known to those skilled in the art.
- the base of Step C is pyridine.
- the oxidizing agent of Step B is an electrophilic halogen reagent.
- electrophilic halogen reagents are known to the skilled practitioner, including dibromine, diiodine, dichlorine, sulfuryl chloride, N-bromosuccinimide, N-iodosuccinimide, N-chlorosuccinimide and 1,3-dibromo-5,5-dimethylhydantoin.
- the oxidizing agent of Step B is N-bromosuccinimide.
- the oxidizing agent of Step B is N-bromosuccinimide, and the subsequent mixture is diluted with an anti-solvent agent.
- the anti-solvent is isopropyl acetate.
- the solvent of Step A comprises tetrahydrofuran
- the base of Step A is lithium diisopropylamide
- the solvent of Step B comprises toluene and ethanol
- the oxidizing agent of Step B is N-bromosuccinimide
- the solvent of Step C comprises tetrahydrofuran
- the base of Step C is pyridine
- the solvent of Step D comprises tetrahydrofuran and water.
- the compound of formula (1) is first contacted with the compound of formula (2) in a reaction mixture comprising a base and solvent, and second optionally contacted with a reaction mixture comprising an aqueous acid or base resulting in the pH of the aqueous phase to be within the range 2 ⁇ pH ⁇ 4, preferably pH 3.
- the base is lithium diisopropylamide and the first solvent is THF, wherein the reaction mixture is maintained such that the internal temperature remains less than ⁇ 5° C., preferably at ⁇ 15° C.
- the pH of the aqueous phase is adjusted to pH 3 with a reaction mixture comprising sulfuric acid, water and toluene.
- the compound of formula (5) is contacted with the compound of formula (7) in a reaction mixture comprising the solvent THF and the base pyridine, and then the base pyridine is removed by addition of saturated saline or aqueous salt (preferably sodium chloride) solution.
- the compound of formula (8) is contacted with the compound of formula (IX) in a reaction mixture comprising a first solvent, such that the compound of formula (10) is formed.
- An aromatic solvent is then added to the mixture, followed by removal of the first solvent by distillation, resulting in the precipitation of the compound of formula (10).
- the aromatic solvent is toluene.
- the compound of formula (1) is particularly useful as a starting material, or an intermediate, in the preparation of the compound of formula (10), as well as chemical analogues of the compound of formula (10).
- the compound of formula (1) can be synthesized in accordance with the preparation methods set forth in Scheme 4 or Scheme 5 herein.
- the term “lower” or “C 1 -C 7 ” denotes a radical having up to and including a maximum of 7, especially up to and including a maximum of 4 carbon atoms, the radicals in question being either linear or branched with single or multiple branching.
- alkyl refers to a straight-chain or branched-chain alkyl group, preferably represents a straight-chain or branched-chain C 1-12 alkyl, particularly preferably represents a straight-chain or branched-chain C 1-7 alkyl; for example, methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, with particular preference given to methyl, ethyl, n-propyl, iso-propyl and n-butyl and iso-butyl.
- Alkyl may be unsubstituted or substituted.
- substituents include, but are not limited to deuterium, hydroxy, alkoxy, halo and amino.
- An example of a substituted alkyl is trifluoromethyl.
- Cycloalkyl may also be a substituent to alkyl. An example of such a case is the moiety (alkyl)-cyclopropyl or alkandiyl-cycloproyl, e.g. —CH 2 -cyclopropyl.
- C 1 -C 7 -alkyl is preferably alkyl with from and including 1 up to and including 7, preferably from and including 1 to and including 4, and is linear or branched; preferably, lower alkyl is butyl, such as n-butyl, sec-butyl, isobutyl, tert-butyl, propyl, such as n-propyl or isopropyl, ethyl or preferably methyl.
- alkyl part of other groups like “alkoxy”, “alkoxyalkyl”, “alkoxycarbonyl”, “alkoxy-carbonylalkyl”, “alkylsulfonyl”, “alkylsulfoxyl”, “alkylamino”, “haloalkyl” shall have the same meaning as described in the above-mentioned definition of “alkyl”
- alkandiyl refers to a straight-chain or branched-chain alkandiyl group bound by two different Carbon atoms to the moiety, it preferably represents a straight-chain or branched-chain C 1-12 alkandiyl, particularly preferably represents a straight-chain or branched-chain C 1-6 alkandiyl; for example, methandiyl (—CH 2 —), 1,2-ethanediyl (—CH 2 —CH 2 —), 1,1-ethanediyl ((—CH(CH 3 )—), 1,1-, 1,2-, 1,3-propanediyl and 1,1-, 1,2-, 1,3-, 1,4-butanediyl, with particular preference given to methandiyl, 1,1-ethanediyl, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl.
- cycloalkyl refers to a saturated or partially saturated, monocyclic, fused polycyclic, or Spiro polycyclic, carbocycle having from 3 to 12 ring atoms per carbocycle.
- Illustrative examples of cycloalkyl groups include the following moieties: cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- Cycloalkyl may be unsubstituted or substituted; exemplary substituents are provided in the definition for alkyl and also include alkyl itself (e.g. methyl).
- a moiety like —(CH 3 )cyclopropyl is considered substituted cycloalkyl.
- aryl refers to an aromatic homocyclic ring system (i.e. only Carbon as ring forming atoms) with 6 or more carbon atoms; aryl is preferably an aromatic moiety with 6 to 14 ring carbon atoms, more preferably with 6 to 10 ring carbon atoms, such as phenyl or naphthyl, preferably phenyl.
- Aryl may be unsubstituted or substituted by one or more, preferably up to three, more preferably up to two substituents independently selected from the group consisting of unsubstituted or substituted heterocyclyl as described below, especially pyrrolidinyl, such as pyrrolidino, oxopyrrolidinyl, such as oxopyrrolidino, C 1 -C 7 -alkyl-pyrrolidinyl, 2,5-di-(C 1 -C 7 alkyl)pyrrolidinyl, such as 2,5-di-(C 1 -C 7 alkyl)-pyrrolidino, tetrahydrofuranyl, thiophenyl, C 1 -C 7 -alkylpyrazolidinyl, pyridinyl, C 1 -C 7 -alkylpiperidinyl, piperidino, piperidino substituted by amino or N-mono- or N,N-di-
- halo halo-lower alkyl
- substituents independently selected from halo, halo-lower alkyl, such as trifluoromethyl, hydroxy, lower alkoxy, azido, amino, N-mono- or N,N-di-(lower alkyl and/or C 1 -C 7 -alkanoyl)-amino, nitro, carboxy, lower-alkoxycarbonyl, carbamoyl, cyano and/or sulfamoyl.
- aryloxy refers to a moiety comprising an oxygen atom that is substituted with an aryl group, as defined above.
- heteroaryl represents a stable monocyclic or bicyclic ring of up to 7 atoms in each ring, wherein at least one ring is aromatic and contains from 1 to 4 heteroatoms selected from the group consisting of O, N and S.
- Heteroaryl groups within the scope of this definition include but are not limited to: acridinyl, carbazolyl, cinnolinyl, quinoxalinyl, pyrrazolyl, indolyl, benzotriazolyl, furanyl, thienyl, benzothienyl, benzofuranyl, quinolinyl, isoquinolinyl, oxazolyl, isoxazolyl, indolyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrahydroquinoline.
- heteroaryl is also understood to include the N-oxide derivative of any nitrogen-containing heteroaryl.
- heteroaryl substituent is bicyclic and one ring is non-aromatic or contains no heteroatoms, it is understood that attachment is via the aromatic ring or via the heteroatom containing ring, respectively.
- the bonding ring i.e.
- heterocyclyl also includes heteroaryl.
- the heterocyclic radical may be unsubstituted or substituted by one or more, especially 1 to 3, substituents independently selected from the group consisting of the substituents defined above for substituted alkyl and/or from one or more of the following substituents: oxo ( ⁇ O), thiocarbonyl ( ⁇ S), imino ( ⁇ NH), imino-lower alkyl.
- heteroatoms are atoms other than Carbon and Hydrogen, preferably nitrogen (N), oxygen (O) or sulfur (S), in particular nitrogen.
- alkyl, alkoxy, aryl, aryloxy and heteroaryl groups described above can be “unsubstituted” or “substituted.”
- substituted is intended to describe moieties having substituents replacing a hydrogen on one or more atoms, e.g. C, O or N, of a molecule.
- substituents can independently include, for example, one or more of the following: straight or branched alkyl (preferably C 1 -C 5 ), cycloalkyl (preferably C 3 -C 8 ), alkoxy (preferably C 1 -C 6 ), thioalkyl (preferably C 1 -C 6 ), alkenyl (preferably C 2 -C 6 ), alkynyl (preferably C 2 -C 6 ), heterocyclic, carbocyclic, aryl (e.g., phenyl), aryloxy (e.g., phenoxy), aralkyl (e.g., benzyl), aryloxyalkyl (e.g., phenyloxyalkyl), arylacetamidoyl, alkylaryl, heteroaralkyl, alkylcarbonyl and arylcarbonyl or other such acyl group, heteroarylcarbonyl, or heteroaryl group, (CR′R′′) 0-3 NR′R′′ (
- halogen refers to fluorine, bromine, chlorine or iodine, in particular fluorine, chlorine.
- Halogen-substituted groups and moieties, such as alkyl substituted by halogen (haloalkyl) can be mono-, poly- or per-halogenated.
- amine or “amino” should be understood as being broadly applied to both a molecule, or a moiety or functional group, as generally understood in the art, and may be primary, secondary, or tertiary.
- amine or “amino” includes compounds where a nitrogen atom is covalently bonded to at least one carbon, hydrogen or heteroatom.
- alkyl amino comprises groups and compounds wherein the nitrogen is bound to at least one additional alkyl group.
- dialkyl amino includes groups wherein the nitrogen atom is bound to at least two additional alkyl groups.
- arylamino and diarylamino include groups wherein the nitrogen is bound to at least one or two aryl groups, respectively.
- alkylarylamino refers to an amino group which is bound to at least one alkyl group and at least one aryl group.
- alkaminoalkyl refers to an alkyl, alkenyl, or alkynyl group bound to a nitrogen atom which is also bound to an alkyl group.
- THF tetrahydrofuran
- RT room temperature
- iPr 2 NH diisopropylamine
- iPr 2 NLi lithium diisopropylamide
- LDA lithium diisopropylamide
- H 2 SO 4 sulfuric acid
- H 2 O water
- IPA isopropyl acetate
- NaCl sodium chloride
- MsCl methanesulfonyl chloride
- NaH sodium hydride
- n-BuLi n-butyllithium
- SF 4 sulfur tetrafluoride
- HCl hydrochloric acid
- HF hydrofluoric acid
- the biphasic mixture was vigorously stirred at room temperature for 25 min. Care was taken that the aqueous layer stayed at 2 ⁇ pH ⁇ 4, preferably pH 3. After phase separation, the organic layer was washed with water, then concentrated at 50° C. under vacuum to ca. 15-20% of its original volume to provide a solution of crude ketone (3) in toluene.
- the reaction vessel was placed in a cooling bath at ⁇ 5° C. to keep the internal temperature between 10-25° C.
- the mixture was diluted with 3 L ethyl acetate and stirred for another 15 minutes.
- the phases were separated, and the water layer was extracted with 2 L ethyl acetate.
- the combined organic phases were washed with 3 L saturated aqueous NaHCO 3 , dried over MgSO 4 , filtered and concentrated in vacuo to give 346 g (106%, 88.6 area % by HPLC) of trifluoromethyl compound (b) as a brown, intensively smelling oil.
- the aqueous layer was extracted with 750 ml ethyl acetate, and the combined organic phases were washed with saturated aqueous NaHCO 3 . Drying over MgSO 4 , filtration and concentration in vacuo provided a beige solid. The residue was redissolved in 300 ml ethyl acetate to give a turbid solution, then filtered over a plug of silica gel (120 g) and eluted with 600 ml ethyl acetate. Concentration in vacuo provided a beige solid which was redissolved in 400 ml heptane and 150 ml ethyl acetate at reflux.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/985,069 US9650373B2 (en) | 2011-03-03 | 2012-03-01 | Synthesis of 2-carboxamide cycloamino urea derivatives |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161448774P | 2011-03-03 | 2011-03-03 | |
PCT/EP2012/053559 WO2012117071A1 (en) | 2011-03-03 | 2012-03-01 | Synthesis of 2-carboxamide cycloamino urea derivatives |
US13/985,069 US9650373B2 (en) | 2011-03-03 | 2012-03-01 | Synthesis of 2-carboxamide cycloamino urea derivatives |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2012/053559 A-371-Of-International WO2012117071A1 (en) | 2011-03-03 | 2012-03-01 | Synthesis of 2-carboxamide cycloamino urea derivatives |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/480,835 Division US9776966B2 (en) | 2011-03-03 | 2017-04-06 | Synthesis of 2-carboxamide cycloamino urea derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
US20130331579A1 US20130331579A1 (en) | 2013-12-12 |
US9650373B2 true US9650373B2 (en) | 2017-05-16 |
Family
ID=45787206
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/985,069 Active US9650373B2 (en) | 2011-03-03 | 2012-03-01 | Synthesis of 2-carboxamide cycloamino urea derivatives |
US15/480,835 Active US9776966B2 (en) | 2011-03-03 | 2017-04-06 | Synthesis of 2-carboxamide cycloamino urea derivatives |
US15/684,419 Active US10059670B2 (en) | 2011-03-03 | 2017-08-23 | Synthesis of 2-carboxamide cycloamino urea derivatives |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/480,835 Active US9776966B2 (en) | 2011-03-03 | 2017-04-06 | Synthesis of 2-carboxamide cycloamino urea derivatives |
US15/684,419 Active US10059670B2 (en) | 2011-03-03 | 2017-08-23 | Synthesis of 2-carboxamide cycloamino urea derivatives |
Country Status (32)
Country | Link |
---|---|
US (3) | US9650373B2 (ru) |
EP (1) | EP2681192B1 (ru) |
JP (1) | JP6022485B2 (ru) |
KR (1) | KR101851421B1 (ru) |
CN (2) | CN106083840B (ru) |
AR (2) | AR088714A1 (ru) |
AU (1) | AU2012222346B2 (ru) |
BR (1) | BR112013021882A2 (ru) |
CA (1) | CA2828509C (ru) |
CL (1) | CL2013002521A1 (ru) |
CO (1) | CO6751286A2 (ru) |
DK (1) | DK2681192T3 (ru) |
EA (4) | EA201892052A1 (ru) |
EC (1) | ECSP13012914A (ru) |
ES (1) | ES2663717T3 (ru) |
GT (1) | GT201300211A (ru) |
HU (1) | HUE036319T2 (ru) |
IL (1) | IL228023A (ru) |
MA (1) | MA34982B1 (ru) |
MX (2) | MX351740B (ru) |
MY (1) | MY163214A (ru) |
NO (1) | NO2681192T3 (ru) |
PE (1) | PE20140917A1 (ru) |
PL (1) | PL2681192T3 (ru) |
PT (1) | PT2681192T (ru) |
SG (1) | SG192793A1 (ru) |
SI (1) | SI2681192T1 (ru) |
TN (1) | TN2013000354A1 (ru) |
TW (2) | TWI607994B (ru) |
UA (1) | UA112539C2 (ru) |
WO (1) | WO2012117071A1 (ru) |
ZA (1) | ZA201306174B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10059670B2 (en) * | 2011-03-03 | 2018-08-28 | Novartis Ag | Synthesis of 2-carboxamide cycloamino urea derivatives |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10227285B2 (en) * | 2014-11-14 | 2019-03-12 | Gemphire Therapeutics Inc. | Processes and intermediates for preparing alpha,omega-dicarboxylic acid-terminated dialkane ethers |
WO2018135632A1 (ja) | 2017-01-20 | 2018-07-26 | 株式会社Peter | スケートボード用ハンドル及びハンドル付きスケートボード |
CN112961090A (zh) * | 2019-12-13 | 2021-06-15 | 武汉九州钰民医药科技有限公司 | 合成Alpelisib的关键中间体及其制备方法 |
CN111057051A (zh) * | 2019-12-16 | 2020-04-24 | 武汉九州钰民医药科技有限公司 | PI3K抑制剂Alpelisib的新合成方法 |
CN110964005A (zh) * | 2019-12-16 | 2020-04-07 | 武汉九州钰民医药科技有限公司 | 一种Alpelisib的制备工艺 |
KR20220125753A (ko) | 2021-03-05 | 2022-09-14 | 배성륭 | 기능성 풍력 발전시스템 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999062890A1 (en) | 1998-06-04 | 1999-12-09 | Pfizer Products Inc. | Isothiazole derivatives useful as anticancer agents |
WO2001017995A1 (en) | 1999-09-10 | 2001-03-15 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2004096797A1 (en) | 2003-05-02 | 2004-11-11 | Novartis Ag | Inhibitors of phosphatidylinositol 3-kinase |
WO2007087427A2 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Thiazole and thiadiazole compounds for inflammation and immune-related uses |
WO2009080694A1 (en) | 2007-12-20 | 2009-07-02 | Novartis Ag | Thiazole derivatives used as pi 3 kinase inhibitors |
WO2010029082A1 (en) | 2008-09-10 | 2010-03-18 | Novartis Ag | Organic compounds |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3534056A (en) * | 1967-03-02 | 1970-10-13 | Pennwalt Corp | Fluoro-alkyl pyridines and their preparation |
TWI428091B (zh) | 2007-10-23 | 2014-03-01 | Du Pont | 殺真菌劑混合物 |
US20100296486A1 (en) * | 2007-12-21 | 2010-11-25 | Carlo Sansone | Method, Apparatus and Computer Program for Handover From A First Access Point To A Second Access Point |
UA112539C2 (uk) * | 2011-03-03 | 2016-09-26 | Новартіс Аг | Спосіб одержання похідних 2-карбоксамідциклоаміносечовини |
-
2012
- 2012-01-03 UA UAA201310018A patent/UA112539C2/uk unknown
- 2012-03-01 SG SG2013062153A patent/SG192793A1/en unknown
- 2012-03-01 DK DK12706843.5T patent/DK2681192T3/en active
- 2012-03-01 MX MX2017005292A patent/MX351740B/es unknown
- 2012-03-01 CN CN201610412757.0A patent/CN106083840B/zh active Active
- 2012-03-01 ES ES12706843.5T patent/ES2663717T3/es active Active
- 2012-03-01 EP EP12706843.5A patent/EP2681192B1/en active Active
- 2012-03-01 EA EA201892052A patent/EA201892052A1/ru unknown
- 2012-03-01 CN CN201280011348.XA patent/CN103402982B/zh active Active
- 2012-03-01 AR ARP120100665A patent/AR088714A1/es active IP Right Grant
- 2012-03-01 EA EA201691331A patent/EA201691331A1/ru unknown
- 2012-03-01 AU AU2012222346A patent/AU2012222346B2/en active Active
- 2012-03-01 PL PL12706843T patent/PL2681192T3/pl unknown
- 2012-03-01 EA EA201391267A patent/EA025381B1/ru not_active IP Right Cessation
- 2012-03-01 EA EA201792068A patent/EA032802B1/ru not_active IP Right Cessation
- 2012-03-01 CA CA2828509A patent/CA2828509C/en active Active
- 2012-03-01 KR KR1020137025764A patent/KR101851421B1/ko active IP Right Grant
- 2012-03-01 MA MA36278A patent/MA34982B1/fr unknown
- 2012-03-01 MX MX2013010132A patent/MX347348B/es active IP Right Grant
- 2012-03-01 SI SI201231240T patent/SI2681192T1/en unknown
- 2012-03-01 MY MYPI2013002966A patent/MY163214A/en unknown
- 2012-03-01 BR BR112013021882A patent/BR112013021882A2/pt not_active Application Discontinuation
- 2012-03-01 JP JP2013555878A patent/JP6022485B2/ja active Active
- 2012-03-01 WO PCT/EP2012/053559 patent/WO2012117071A1/en active Application Filing
- 2012-03-01 PE PE2013002003A patent/PE20140917A1/es not_active Application Discontinuation
- 2012-03-01 HU HUE12706843A patent/HUE036319T2/hu unknown
- 2012-03-01 PT PT127068435T patent/PT2681192T/pt unknown
- 2012-03-01 US US13/985,069 patent/US9650373B2/en active Active
- 2012-03-01 NO NO12706843A patent/NO2681192T3/no unknown
- 2012-03-02 TW TW106106845A patent/TWI607994B/zh not_active IP Right Cessation
- 2012-03-02 TW TW101107070A patent/TWI597279B/zh not_active IP Right Cessation
-
2013
- 2013-08-16 ZA ZA2013/06174A patent/ZA201306174B/en unknown
- 2013-08-19 IL IL228023A patent/IL228023A/en active IP Right Grant
- 2013-08-28 GT GT201300211A patent/GT201300211A/es unknown
- 2013-08-28 TN TNP2013000354A patent/TN2013000354A1/fr unknown
- 2013-08-30 CO CO13206319A patent/CO6751286A2/es unknown
- 2013-09-02 CL CL2013002521A patent/CL2013002521A1/es unknown
- 2013-10-02 EC ECSP13012914 patent/ECSP13012914A/es unknown
-
2017
- 2017-04-06 US US15/480,835 patent/US9776966B2/en active Active
- 2017-08-23 US US15/684,419 patent/US10059670B2/en active Active
-
2021
- 2021-09-23 AR ARP210102644A patent/AR123584A2/es unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999062890A1 (en) | 1998-06-04 | 1999-12-09 | Pfizer Products Inc. | Isothiazole derivatives useful as anticancer agents |
WO2001017995A1 (en) | 1999-09-10 | 2001-03-15 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2004096797A1 (en) | 2003-05-02 | 2004-11-11 | Novartis Ag | Inhibitors of phosphatidylinositol 3-kinase |
WO2007087427A2 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Thiazole and thiadiazole compounds for inflammation and immune-related uses |
WO2009080694A1 (en) | 2007-12-20 | 2009-07-02 | Novartis Ag | Thiazole derivatives used as pi 3 kinase inhibitors |
WO2010029082A1 (en) | 2008-09-10 | 2010-03-18 | Novartis Ag | Organic compounds |
Non-Patent Citations (2)
Title |
---|
Gallagher, Sai. et al. Aromatic N-Oxides. V. The Reaction of 4-Picoline N-Oxide with Various Anhydrides. Journal of the American Chemical Society. 1965, vol. 87, p. 5714. * |
Sarkis G Y et al: "Preparation and spectral characterization of substituted 2-aminothiazoles", Journal of Chemical and Engineering Data, American Chemical Society, US, vol. 18, No. 1, Jan. 1, 1973, pp. 99-102. |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10059670B2 (en) * | 2011-03-03 | 2018-08-28 | Novartis Ag | Synthesis of 2-carboxamide cycloamino urea derivatives |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10059670B2 (en) | Synthesis of 2-carboxamide cycloamino urea derivatives | |
JP5243696B2 (ja) | ベンゼン誘導体 | |
WO2009076747A1 (en) | Viral polymerase inhibitors | |
CA3157798A1 (en) | 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity | |
WO2016040952A2 (en) | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | |
AU2011209685B2 (en) | Therapeutic agents for treatment of ocular hypertension | |
CN103724352B (zh) | 一种dpp‑iv抑制剂的中间体、其制备方法和通过其制备dpp‑iv抑制剂的方法 | |
WO2016023522A2 (en) | Substituted phosphoramidate compounds and uses thereof | |
NZ614173B2 (en) | Synthesis of 2-carboxamide cycloamino urea derivatives | |
CA3194774A1 (en) | Tetrahydroisoquinoline derivatives for the treatment of red blood disorders and inflammatory diseases | |
JP2008543761A (ja) | 3−アミノ−4−置換ピラゾール誘導体の合成 | |
CA3002920A1 (en) | Method for removing dimethoxybenzyl group | |
EP3201192A1 (en) | Ester prodrugs of gamma-lactams and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS PHARMA AG;REEL/FRAME:031156/0219 Effective date: 20120208 Owner name: NOVARTIS PHARMA AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ERB, BERNARD;GALLOU, ISABELLE SYLVIE;KLEINBECK, FLORIAN KARL;REEL/FRAME:031131/0465 Effective date: 20120201 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: NOVARTIS PHARMA AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ERB, BERNARD;GALLOU, ISABELLE SYLVIE;KLEINBECK, FLORIAN KARL;REEL/FRAME:046271/0978 Effective date: 20120201 Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS PHARMA AG;REEL/FRAME:046492/0455 Effective date: 20120208 |
|
AS | Assignment |
Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS PHARMA AG;REEL/FRAME:046289/0482 Effective date: 20120208 Owner name: NOVARTIS PHARMA AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ERB, BERNARD;GALLOU, ISABELLE SYLVIE;KLEINBECK, FLORIAN KARL;REEL/FRAME:046289/0443 Effective date: 20120201 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |